Cargando…

The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors

Protein arginine methyltransferase 1 (PRMT1) can catalyze protein arginine methylation by transferring the methyl group from S-adenosyl-L-methionine (SAM) to the guanidyl nitrogen atom of protein arginine, which influences a variety of biological processes. The dysregulation of PRMT1 is involved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yutong, Wang, Zhe, Yang, Hao, Zhu, Xuanli, Wu, Han, Ma, Lu, Xu, Fang, Hong, Wei, Wang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695598/
https://www.ncbi.nlm.nih.gov/pubmed/31390828
http://dx.doi.org/10.3390/ijms20153840
_version_ 1783444072826929152
author Sun, Yutong
Wang, Zhe
Yang, Hao
Zhu, Xuanli
Wu, Han
Ma, Lu
Xu, Fang
Hong, Wei
Wang, Hao
author_facet Sun, Yutong
Wang, Zhe
Yang, Hao
Zhu, Xuanli
Wu, Han
Ma, Lu
Xu, Fang
Hong, Wei
Wang, Hao
author_sort Sun, Yutong
collection PubMed
description Protein arginine methyltransferase 1 (PRMT1) can catalyze protein arginine methylation by transferring the methyl group from S-adenosyl-L-methionine (SAM) to the guanidyl nitrogen atom of protein arginine, which influences a variety of biological processes. The dysregulation of PRMT1 is involved in a diverse range of diseases, including cancer. Therefore, there is an urgent need to develop novel and potent PRMT1 inhibitors. In the current manuscript, a series of 1-substituted 1H-tetrazole derivatives were designed and synthesized by targeting at the substrate arginine-binding site on PRMT1, and five compounds demonstrated significant inhibitory effects against PRMT1. The most potent PRMT1 inhibitor, compound 9a, displayed non-competitive pattern with respect to either SAM or substrate arginine, and showed the strong selectivity to PRMT1 compared to PRMT5, which belongs to the type II PRMT family. It was observed that the compound 9a inhibited the functions of PRMT1 and relative factors within this pathway, and down-regulated the canonical Wnt/β-catenin signaling pathway. The binding of compound 9a to PRMT1 was carefully analyzed by using molecular dynamic simulations and binding free energy calculations. These studies demonstrate that 9a was a potent PRMT1 inhibitor, which could be used as lead compound for further drug discovery.
format Online
Article
Text
id pubmed-6695598
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66955982019-09-05 The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors Sun, Yutong Wang, Zhe Yang, Hao Zhu, Xuanli Wu, Han Ma, Lu Xu, Fang Hong, Wei Wang, Hao Int J Mol Sci Article Protein arginine methyltransferase 1 (PRMT1) can catalyze protein arginine methylation by transferring the methyl group from S-adenosyl-L-methionine (SAM) to the guanidyl nitrogen atom of protein arginine, which influences a variety of biological processes. The dysregulation of PRMT1 is involved in a diverse range of diseases, including cancer. Therefore, there is an urgent need to develop novel and potent PRMT1 inhibitors. In the current manuscript, a series of 1-substituted 1H-tetrazole derivatives were designed and synthesized by targeting at the substrate arginine-binding site on PRMT1, and five compounds demonstrated significant inhibitory effects against PRMT1. The most potent PRMT1 inhibitor, compound 9a, displayed non-competitive pattern with respect to either SAM or substrate arginine, and showed the strong selectivity to PRMT1 compared to PRMT5, which belongs to the type II PRMT family. It was observed that the compound 9a inhibited the functions of PRMT1 and relative factors within this pathway, and down-regulated the canonical Wnt/β-catenin signaling pathway. The binding of compound 9a to PRMT1 was carefully analyzed by using molecular dynamic simulations and binding free energy calculations. These studies demonstrate that 9a was a potent PRMT1 inhibitor, which could be used as lead compound for further drug discovery. MDPI 2019-08-06 /pmc/articles/PMC6695598/ /pubmed/31390828 http://dx.doi.org/10.3390/ijms20153840 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sun, Yutong
Wang, Zhe
Yang, Hao
Zhu, Xuanli
Wu, Han
Ma, Lu
Xu, Fang
Hong, Wei
Wang, Hao
The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
title The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
title_full The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
title_fullStr The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
title_full_unstemmed The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
title_short The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors
title_sort development of tetrazole derivatives as protein arginine methyltransferase i (prmt i) inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695598/
https://www.ncbi.nlm.nih.gov/pubmed/31390828
http://dx.doi.org/10.3390/ijms20153840
work_keys_str_mv AT sunyutong thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT wangzhe thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT yanghao thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT zhuxuanli thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT wuhan thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT malu thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT xufang thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT hongwei thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT wanghao thedevelopmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT sunyutong developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT wangzhe developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT yanghao developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT zhuxuanli developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT wuhan developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT malu developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT xufang developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT hongwei developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors
AT wanghao developmentoftetrazolederivativesasproteinargininemethyltransferaseiprmtiinhibitors